Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)
Status:
Completed
Trial end date:
2021-06-28
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized trial to study the potential benefit of treatments
with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low
molecular weight heparin (LMWH) (Lovenox) in hospitalized subjects with COVID-19.